Pierre Fabre Supercritical Fluids heads for Big Sight Tokyo – CPhI / ICSE Japan

news-releasesPierre Fabre Médicament: Supercritical Fluids Division
March 5th 2015

Gaillac, France: – One of France’s most innovative pharmaceutical companies, Pierre Fabre Medicament Supercritical Fluids Division, will exhibit its breakthrough technologies at April’s ICSE outsourcing event, part of the landmark CPhI Japan 2015 expo.

The Supercritical Fluids team at Booth 1H-37 at Tokyo’s Big Sight Exhibition Centre will have news of the latest advances made in application of supercritical carbon dioxide to pharmaceutical applications, using its patented Formulcoat®, Formulplex® and Formuldisp® technologies.

These include enhancement of drug delivery, extraction for pharmaceuticals, along with purification, extraction of leachables and scouring.

The team will be assisted by a trilingual translator, fluent in English, French and Japanese.

Ibuprofen breakthrough processes

Late last year, Supercritical Fluids posted details of the application of Formulcoat (taste-masking process) to the western world’s most popular painkiller, ibuprofen.

Easing cGMP manufacture

“At Big Sight, we will be showing our visitors how our unique services make development of new NCEs possible, allow new API formulations for Life Cycle Management and also allow pharma companies to find a partner for the manufacturing of their cGMP batches by supercritical CO2 ,” explained Bernard Freiss, Head of Supercritical Fluids department.

“We’ll also be showing ways for clients to transfer their whole process into Supercritical Fluids state of the art facilities to optimize production and carry out demanding cGMP manufacture in batches,” he added.

Supercritical Fluids is also equipped with specific manufacturing areas (illustrated) to handle highly potent substances.

About Pierre Fabre Medicament

Pierre Fabre Médicament is one of France’s largest independent pharmaceutical laboratories, focusing on ethical drugs, health products and dermocosmetic products.

Located in the French Midi-Pyrenees Department, Pierre Fabre has a presence in more than 130 countries worldwide and has a combined workforce of more than 10,000 people of whom more than 3.000 work outside France.

Founded in 1962, company’s business activity is focused on research, development, manufacturing and marketing of cosmetics, prescription medicines and family health products. Almost half of sales are represented by pharmaceuticals and phytotherapy, with cosmetics representing the remainder.

Pierre Fabre is especially known for its vinca alkaloid anticancer drug Navelbine (vinorelbine).

Pierre Fabre Medicaments Production (PFMP) has developed a broad range of contract services for external partners around the world. PFMP provides innovative solutions in dedicated plants per drug forms.

PFMP’s six manufacturing sites are able to develop and manufacture active ingredients, dry forms (tablets and capsules) liquid and semi-solid forms, lozenges and injectables. PFMP plants are approved to FDA, PMDA, ANVISA and EMEA standards.

Pierre Fabre’s Supercritical Fluids division has developed specialized expertise in supercritical fluids technology for pharmaceutical applications, in particular in Drug Delivery Systems (DDS).

In particular, PFM SuperCritical Fluids is responsible for the development and application of Pierre Fabre Medicament’s Formulplex® Formuldisp® and Formulcoat® processes .

About ICSE Japan 2015

The ICSE Japan expo is part of CPhI Japan, one of the region’s premier pharma business and sourcing events, offering delegates opportunities to arrange face-to-face meetings with potential international partners and collaborators, as well as gain insights on latest industry trends.

CPhI 2015 is being held April 22 – 24 at Tokyo’s Big Sight Exhibition Centre, alongside four other zoned exhibitions; P-MEC (including LabWorld) for machinery and equipment, ICSE for outsourcing solutions, BioPh for bio-technology and InnoPack for Drug Packaging and Delivery Technology.

It’s is expected to be the biggest CPhI Japan event to date, attracting close to 19,000 visitors, compared with 17,275 for the 2014 event. The event also attracts more than 400 exhibiting companies, representing 28 countries. The 2015 expo will feature national pavilions for Japan, China, South Korea, UK, India and Italy.

CPhl is staged by leading global B2B events organizer and publisher, UBM Live.

More information at: http://www.cphi.com/japan/home

View Articles by Pierre Fabre Médicament: Supercritical Fluids Division